Diaceutics PLC (LON:DXRX) Insider Jordan Clark Purchases 104 Shares

Diaceutics PLC (LON:DXRX) insider Jordan Clark purchased 104 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was acquired at an average price of GBX 144 ($1.79) per share, for a total transaction of £149.76 ($185.99).

Diaceutics Stock Down 2.2 %

DXRX stock opened at GBX 135.50 ($1.68) on Friday. The company has a debt-to-equity ratio of 2.93, a current ratio of 4.85 and a quick ratio of 9.92. The firm has a market capitalization of £114.46 million, a P/E ratio of -4,516.67 and a beta of 0.58. Diaceutics PLC has a 52-week low of GBX 92.24 ($1.15) and a 52-week high of GBX 151 ($1.88). The company’s 50 day simple moving average is GBX 129.50 and its 200-day simple moving average is GBX 128.53.

Analyst Upgrades and Downgrades

DXRX has been the subject of several research reports. Canaccord Genuity Group reissued a “buy” rating and set a GBX 160 ($1.99) price objective on shares of Diaceutics in a research note on Tuesday, December 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 160 ($1.99) price target on shares of Diaceutics in a research report on Tuesday, December 17th.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.